|
|
GLP-1RA联合SGLT2抑制剂治疗糖尿病肾病的Meta分析
|
Abstract:
目的：运用Meta分析的方法评估GLP-1RA联合SGLT-2i抑制剂治疗糖尿病肾病的有效性和安全性。方法：检索CNKI、万方数据库、VIP、SinoMed、PubMed、Embase、Cochrane Library、Ovid、Web of Science中关于GLP-1RA联合SGLT-2i治疗糖尿病肾病的实验性研究，检索时间从各数据库建库至2023年6月25日。主要结局指标包括糖化血红蛋白(HbA1c)、血清肌酐(Scr)、尿素氮(BUN)、尿微量白蛋白肌酐比值(UACR)、估计肾小球滤过率(eGFR)、低血糖发生率。采用RevMan5.4和Stata16.0进行Meta分析。结果：本研究共纳入10篇文献，分析结果显示在有效性方面GLP-1RA联合SGLT-2i与单用GLP-1RA或SGLT-2i相比在降低HbA1c [WMD = ？0.506, 95% CI (？0.786, ？0.227), P = 0.000]、Scr [WMD = ？8.21, 95% CI (？12.55, ？3.87), P = 0.000]、BUN [WMD = ？1.224, 95% CI (？1.674, ？0.774), P = 0.000]、UACR [WMD = ？20.94, 95% CI (？32.89, ？8.99), P = 0.000]方面具有优势，但在降低eGFR方面联合治疗并不优于单药治疗[WMD = ？3.310, 95% CI (？13.073, 6.454), P = 0.506]。亚组分析结果显示当疗程大于3个月时，GLP-1RA联合SGLT-2i降低HbA1C、Scr、BUN的效果与单药相比无明显差异(PHbA1c = 0.770, PScr = 0.735, PBUN = 0.855)。在安全性方面，GLP-1RA联合SGLT-2i不会增加低血糖的发生风险[OR = 1.818, 95% CI (0.799, 4.139), P = 0.154]。结论：GLP-1RA联合SGLT-2i与单用GLP-1RA或SGLT-2i比较，能有效降低HbA1c、Scr、BUN、UACR水平，且不会增加低血糖发生风险，具有良好的有效性和安全性。
Objective: To use Meta analysis method to evaluate the effectiveness and safety of GLP-1RA com-bined with SGLT-2i inhibitors in the treatment of diabetic nephropathy. Methods: Search CNKI, Wanfang Database, VIP, SinoMed, PubMed, Embase, Cochrane Library, Ovid, and Web of Science for experimental studies on GLP-1RA combined with SGLT-2i in the treatment of diabetic nephropathy. The search time was from the establishment of each database to June 25, 2023. The main outcome indicators included glycosylated hemoglobin (HbA1c), serum creatinine (Scr), urea nitrogen (BUN), urinary microalbumin to creatinine ratio (UACR), estiMetad glomerular filtration rate (eGFR), and the incidence of hypoglycemia. RevMan5.4 and Stata16.0 were used for Meta analysis. Results: A total of 10 documents were included in this study, and the analysis results showed that in terms of effectiveness, GLP-1RA combined with SGLT-2i was more effective in reducing HbA1c than GLP-1RA or SGLT-2i alone [WMD = ？0.506, 95% CI (？0.786, ？0.227), P = 0.000], Scr [WMD = ？8.21, 95% CI (？12.55, ？3.87), P = 0.000], BUN [WMD = ？1.224, 95% CI (？1.674, ？0.774), P = 0.000], UACR [WMD = ？20.94, 95% CI (？32.89, ？8.99), P = 0.000] has advantages, but combination therapy is not better than monotherapy in reducing eGFR [WMD = ？3.310, 95% CI (？13.073, 6.454), P = 0.506]. Sub-group analysis results showed that when the treatment course was more than 3 months, the effect of GLP-1RA combined with SGLT-2i in reducing HbA1C, Scr, and BUN was not significantly different from that of single drug (PHbA1c = 0.770, PScr = 0.735,
| [1] | International Diabetes Federation (2021) IDF Diabetes Atlas. 10th Edition, International Diabetes Federation, Brus-sels. |
| [2] | 陈玉强, 汪年松. 糖尿病肾病的诊治现状[J]. 中国临床医生杂志, 2020, 48(5): 508-511. |
| [3] | Jung, C.Y. and Yoo, T.H. (2022) Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease. Diabetes & Metabolism Journal, 46, 181-197. https://doi.org/10.4093/dmj.2021.0329 |
| [4] | Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P. and Susztak, K. (2023) Molecular Pathways That Drive Diabetic Kidney Disease. Journal of Clinical Investigation, 133, e165654. https://doi.org/10.1172/JCI165654 |
| [5] | Zhang, Z., Liang, W., Luo, Q., Hu, H., Yang, K., Hu, J., Chen, Z., Zhu, J., Feng, J., Zhu, Z., Chi, Q. and Ding, G. (2022) PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease. Frontiers in Endocrinology (Lausanne), 12, Article ID: 797025. https://doi.org/10.3389/fendo.2021.797025 |
| [6] | Rossing, P., Caramori, M.L., Chan, J.C.N., et al. (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127. https://doi.org/10.1016/j.kint.2022.06.008 |
| [7] | 贺巧艳, 白若玥, 王湘. 达格列净联合利拉鲁肽对糖尿病肾病患者血清炎症因子水平及蛋白尿的影响[J]. 临床医学研究与实践, 2022, 7(29): 40-43. https://doi.org/10.19347/j.cnki.2096-1413.202229011 |
| [8] | 叶丽姿, 周圣明, 阳焕军. 达格列净联合利拉鲁肽治疗2型糖尿病肾病的效果及安全性研究[J]. 中国医学创新, 2022, 19(32): 6-11. |
| [9] | 刘琳. 达格列净联合利拉鲁肽注射液对糖尿病肾病患者蛋白尿的影响[J]. 慢性病学杂志, 2021, 22(6): 970-972.
https://doi.org/10.16440/j.cnki.1674-8166.2021.06.050 |
| [10] | 秦莉, 张秋菊. 达格列净联合利拉鲁肽注射液对糖尿病肾病患者蛋白尿的影响观察[J]. 中国医药科学, 2022, 12(20): 78-81. |
| [11] | 邢建东, 姚艳琴, 王静茹, 等. 度拉糖肽联合达格列净对早期糖尿病肾病尿蛋白排泄率及血清炎性因子的影响[J]. 疑难病杂志, 2022, 21(11): 1158-1162+1168. |
| [12] | 蒙绪标, 罗德钦, 林珠, 等. 利拉鲁肽联合达格列净对糖尿病肾病患者促代谢因子及左室射血分数的影响[J]. 大医生, 2022, 7(11): 20-22. |
| [13] | 肖娇, 李国娟, 肖自幼, 等. 利拉鲁肽与达格列净联合治疗2型糖尿病肾病的临床疗效分析[J]. 糖尿病新世界, 2021, 24(3): 168-170. https://doi.org/10.16658/j.cnki.1672-4062.2021.03.168 |
| [14] | 何黎, 郑世玲, 庄小军. 利拉鲁肽联合达格列净方案在糖尿病肾脏疾病中的治疗效果分析[J]. 健康必读, 2022(8): 1-3, 8. |
| [15] | 张千. 利拉鲁肽联合达格列净对2型糖尿病早期肾脏病患者的临床疗效观察[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2022. |
| [16] | 刘玲. 利拉鲁肽与达格列净对2型糖尿病早期肾病的疗效观察[D]: [硕士学位论文]. 长沙: 湖南师范大学, 2021. |
| [17] | Kuang, Z., Hou, N., Kan, C., et al. (2023) The Protective Effects of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and RAAS Blockers against Renal Injury in Patients with Type 2 Diabetes. International Urology and Nephrology, 55, 617-629. https://doi.org/10.1007/s11255-022-03355-6 |
| [18] | Sindhu, D., Sharma, G.S. and Kumbala, D. (2023) Management of Diabetic Kidney Disease: Where Do We Stand? A Narrative Review. Medicine, 102, e33366. https://doi.org/10.1097/MD.0000000000033366 |
| [19] | Ikonomidis, I., Pavlidis, G., Thymis, J., et al. (2020) Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients with Type 2 Diabetes Mellitus after 12-Month Treatment. Journal of the American Heart Association, 9, e015716. https://doi.org/10.1161/JAHA.119.015716 |
| [20] | Górriz, J.L., Soler, M.J., Navarro-González, J.F., et al. (2020) GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medi-cine, 9, 947. https://doi.org/10.3390/jcm9040947 |
| [21] | De Cosmo, S., Viazzi, F., Piscitelli, P., et al. (2019) Impact of CVOTs in Primary and Secondary Prevention of Kidney Disease. Diabetes Research and Clinical Practice, 157, Arti-cle ID: 107907.
https://doi.org/10.1016/j.diabres.2019.107907 |
| [22] | Zelniker, T.A. and Braunwald, E. (2020) Mechanisms of Car-diorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75, 422-434.
https://doi.org/10.1016/j.jacc.2019.11.031 |
| [23] | Oshima, M., Neuen, B.L., Li, J.W., et al. (2020) Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 31, 2925-2936. https://doi.org/10.1681/ASN.2020050723 |
| [24] | Bailey, C.J. (2019) Uric Acid and the Cardio-Renal Effects of SGLT2 Inhibitors. Diabetes, Obesity and Metabolism, 21, 1291-1298. https://doi.org/10.1111/dom.13670 |
| [25] | Sun, X., Han, F., Lu, Q., et al. (2020) Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice. Diabetes, 69, 1292-1305. https://doi.org/10.2337/db19-0991 |
| [26] | Yaribeygi, H., Atkin, S.L., Butler, A.E., et al. (2019) So-dium-Glucose Cotransporter Inhibitors and Oxidative Stress: An Update. Journal of Cellular Physiology, 234, 3231-3237. https://doi.org/10.1002/jcp.26760 |
| [27] | Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J. and Stompór, T. (2021) Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences, 22, Article No. 10822. https://doi.org/10.3390/ijms221910822 |
| [28] | Zelniker, T.A., Wiviott, S.D., Raz, I., et al. (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation, 139, 2022-2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868 |
| [29] | Mann, J.F.E., Fonseca, V., Mosenzon, O., et al. (2018) Effects of Liraglutide versus Placebo on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results from the LEADER Trial. Circulation, 138, 2908-2918. https://doi.org/10.1161/CIRCULATIONAHA.118.036418 |
| [30] | Tuttle, K.R., Lakshmanan, M.C., Rayner, B., et al. (2018) Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7): A Multicentre, Open-Label, Randomised Trial. The Lancet Diabetes & Endocrinology, 6, 605-617. https://doi.org/10.1016/S2213-8587(18)30104-9 |
